Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling
Cannabinoids include not only plant-derived compounds (of which Δ9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. C...
Saved in:
| Published in | Biological reviews of the Cambridge Philosophical Society Vol. 79; no. 1; pp. 187 - 205 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Cambridge University Press
01.02.2004
Blackwell Publishing Ltd |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1464-7931 1469-185X |
| DOI | 10.1017/S1464793103006201 |
Cover
Loading…
| Abstract | Cannabinoids include not only plant-derived compounds (of which Δ9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB1 receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. |
|---|---|
| AbstractList | Cannabinoids include not only plant-derived compounds (of which delta9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB, receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest.Cannabinoids include not only plant-derived compounds (of which delta9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB, receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. Cannabinoids include not only plant-derived compounds (of which [Delta]9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB1 receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. [PUBLICATION ABSTRACT] ABSTRACT Cannabinoids include not only plant‐derived compounds (of which Δ9‐tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2‐arachidonoylethanolamide) and 2‐arachidonoylglycerol. Cannabinoids act on specific, G‐protein‐coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non‐cannabinoid receptor‐mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB1 receptors may activate the extracellular signal‐regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene‐related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. Cannabinoids include not only plant-derived compounds (of which Δ9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB1 receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. Cannabinoids include not only plant‐derived compounds (of which Δ 9 ‐tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2‐arachidonoylethanolamide) and 2‐arachidonoylglycerol. Cannabinoids act on specific, G‐protein‐coupled, receptors which are currently divided into two types, CB 1 and CB 2 . Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB 1 receptors has non‐cannabinoid receptor‐mediated effects at concentrations which are often used to define the presence of the CB 1 receptor. Both cannabinoid receptors are primarily coupled to G i/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB 1 receptors also modulates the activity of K + and Ca 2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB 1 receptors may activate the extracellular signal‐regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB 1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to G i/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene‐related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. Cannabinoids include not only plant-derived compounds (of which delta9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic agents and endogenous substances termed endocannabinoids which include anandamide (2-arachidonoylethanolamide) and 2-arachidonoylglycerol. Cannabinoids act on specific, G-protein-coupled, receptors which are currently divided into two types, CB1 and CB2. Relatively selective agonists and antagonists for these receptors have been developed, although one agent (SR141716A) widely used as an antagonist at CB1 receptors has non-cannabinoid receptor-mediated effects at concentrations which are often used to define the presence of the CB1 receptor. Both cannabinoid receptors are primarily coupled to Gi/o proteins and act to inhibit adenylyl cyclase. Stimulation of CB1 receptors also modulates the activity of K+ and Ca2+ channels and of protein kinase pathways including protein kinase B (Akt) which might mediate effects on apoptosis. CB, receptors may activate the extracellular signal-regulated kinase cascade through ceramide signalling. Cannabinoid actions on the cardiovascular system have been widely interpreted as being mediated by CB1 receptors although there are a growing number of observations, particularly in isolated heart and blood vessel preparations, that suggest that other cannabinoid receptors may exist. Interestingly, the currently identified cannabinoid receptors appear to be related to a wider family of lipid receptor, those for the lysophospholipids, which are also linked to Gi/o protein signalling. Anandamide also activates vanilloid VR1 receptors on sensory nerves and releases the vasoactive peptide, calcitonin gene-related peptide (CGRP), which brings about vasodilatation through its action on CGRP receptors. Current evidence suggests that endocannabinoids have important protective roles in pathophysiological conditions such as shock and myocardial infarction. Therefore, their cardiovascular effects and the receptors mediating them are the subject of increasing investigative interest. |
| Author | Hiley, C. Robin Ford, William R. |
| Author_xml | – sequence: 1 givenname: C. Robin surname: Hiley fullname: Hiley, C. Robin email: crh1@cam.ac.uk organization: Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK (E-mail: crh1@cam.ac.uk) – sequence: 2 givenname: William R. surname: Ford fullname: Ford, William R. email: crh1@cam.ac.uk organization: Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, UK (E-mail: crh1@cam.ac.uk) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15005177$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU1v1DAQhi1URD_gB3BBEQduATu2Y4cbXaAFlSLxUbhZs46TdXHsYCeF_fd42YVKRcDJo5n3mXk9c4j2fPAGofsEPyaYiCfvCauZaCjBFOO6wuQWOsippiSSf977GbNyU99HhyldYpwTNb2D9gnHmBMhDlBYgPewtD7YthhXEAfQwYV-XVhfTCtTaIitDVeQ9OwgFmmdJjM8LcYwGT9ZcMUYc6gne2WKwegVeJuGlNEY5n5VODvmxsn2Hpyzvr-Lbnfgkrm3e4_Qx5cvPixOy7O3J68Wz85KzXglypa0mteEVRikpryqccsqQ3XVyE42hBvaSMm6li9Jwzqtay0kUFYBrnj-paFH6NG2b7b3dTZpUoNN2jgH3oQ5KUEEwZKRLHx4Q3gZ5pjdJlVR0mBZYZZFD3aieTmYVo3RDhDX6tces4BsBTqGlKLpriVYbW6l_rhVZsQNRtsJJhv8FMG6f5J8S36zzqz_P0odv7sgcuOy3HI2H_H7bw7iF1ULKrj6dH6iXp8-r9_U5xdqM4fuHMKwjLbtzfVy_u7uBzDBxRg |
| CODEN | BRCPAH |
| CitedBy_id | crossref_primary_10_1053_j_gastro_2005_05_026 crossref_primary_10_1016_j_sjbs_2021_08_036 crossref_primary_10_1038_sj_bjp_0707582 crossref_primary_10_1038_sj_bjp_0707261 crossref_primary_10_1007_s10557_021_07307_7 crossref_primary_10_1016_j_cnr_2005_08_015 crossref_primary_10_1093_alcalc_agh110 crossref_primary_10_5507_bp_2014_043 crossref_primary_10_1002_cbdv_200790161 crossref_primary_10_1016_j_lfs_2007_01_062 crossref_primary_10_3390_jpm13020372 crossref_primary_10_1073_pnas_0510676103 crossref_primary_10_25040_lkv2013_01_054 crossref_primary_10_1016_j_crohns_2014_01_025 crossref_primary_10_1016_j_lfs_2005_05_005 crossref_primary_10_1038_sj_bjp_0706643 crossref_primary_10_4239_wjd_v13_i5_387 crossref_primary_10_3390_medicina55120752 crossref_primary_10_1097_FJC_0b013e318192671d crossref_primary_10_1016_j_cvdpc_2010_08_002 crossref_primary_10_1074_jbc_C500175200 crossref_primary_10_1371_journal_pone_0063386 crossref_primary_10_1002_ptr_5265 crossref_primary_10_1211_0022357023682 crossref_primary_10_1097_CRD_0000000000000720 crossref_primary_10_1136_bmjopen_2016_011891 crossref_primary_10_1002_hep_20714 crossref_primary_10_1155_2011_469850 crossref_primary_10_1016_j_jpeds_2015_06_001 crossref_primary_10_1124_pr_58_3_2 crossref_primary_10_2165_00129784_200707040_00005 crossref_primary_10_1038_sj_bjp_0706195 crossref_primary_10_1016_j_yjmcc_2009_10_025 crossref_primary_10_1111_ijcp_13477 crossref_primary_10_1530_JOE_13_0192 crossref_primary_10_1016_j_bcp_2005_03_027 crossref_primary_10_1111_bph_13107 crossref_primary_10_3917_psyt_223_0157 crossref_primary_10_1007_s12012_015_9332_0 crossref_primary_10_1016_j_neuropharm_2004_12_005 crossref_primary_10_1097_HJH_0b013e3282ef7a0a crossref_primary_10_1016_j_lfs_2008_04_023 crossref_primary_10_1152_physrev_00024_2010 crossref_primary_10_1152_physrev_00002_2016 crossref_primary_10_1093_eurheartj_ehr246 crossref_primary_10_3803_jkes_2008_23_4_223 crossref_primary_10_1111_j_1476_5381_2009_00518_x crossref_primary_10_1016_j_cacc_2005_03_004 crossref_primary_10_1002_1873_3468_12863 crossref_primary_10_1016_j_tips_2012_03_002 |
| Cites_doi | 10.1161/01.HYP.33.1.429 10.1038/sj.bjp.0702337 10.1016/S0024-3205(02)02474-8 10.1210/en.141.5.1675 10.1016/S0008-6363(02)00268-7 10.1124/mol.63.3.699 10.1016/S0014-2999(01)00940-2 10.1038/73171 10.1126/science.277.5329.1094 10.1042/bj3460835 10.1111/j.1476-5381.1973.tb08262.x 10.1016/S0197-0186(01)00076-6 10.1073/pnas.92.8.3376 10.1074/jbc.270.8.3726 10.1016/S0014-2999(97)01237-5 10.1046/j.1471-4159.1998.71041525.x 10.1007/s001090050287 10.1517/13543784.9.7.1553 10.1038/346561a0 10.1038/sj.bjp.0702452 10.1021/ja01062a046 10.1016/S0005-2760(98)00110-6 10.1111/j.1476-5381.1992.tb09088.x 10.1038/sj.bjp.0705156 10.1074/jbc.M107351200 10.1111/j.1476-5381.1996.tb15639.x 10.1182/blood-2002-05-1444 10.1038/sj.bjp.0701361 10.1016/S0024-3205(02)02086-6 10.1038/384083a0 10.1006/bbrc.1998.8187 10.1016/S0735-1097(01)01671-0 10.1124/jpet.301.3.1020 10.1096/fasebj.12.11.1035 10.1038/sj.bjp.0702127 10.1016/0091-3057(91)90349-7 10.1038/sj.bjp.0703094 10.1016/S0163-7258(02)00258-9 10.1021/jm00079a016 10.1074/jbc.M008555200 10.1046/j.1471-4159.2000.0752434.x 10.1152/ajpheart.1998.274.1.H375 10.1016/0014-5793(95)01194-J 10.1016/0014-5793(95)01207-U 10.1074/jbc.M005722200 10.1016/S1096-4959(02)00003-9 10.1126/science.283.5400.401 10.1016/S0166-2236(98)01283-1 10.1042/bj3470369 10.1038/sj.bjp.0704333 10.1146/annurev.pharmtox.41.1.507 10.1124/mol.54.1.180 10.1006/bbrc.1996.1553 10.1016/S0165-6147(00)01586-8 10.1042/bj3510817 10.1124/pr.54.2.161 10.1016/S0014-2999(98)00649-9 10.1038/sj.bjp.0702483 10.1038/42015 10.1042/bj3310015 10.1172/JCI119677 10.1016/S0304-3940(97)00851-3 10.1074/jbc.271.17.9902 10.1124/pr.54.2.265 10.1016/S0009-3084(99)00124-3 10.1074/jbc.275.1.605 10.1097/00003246-200203000-00009 10.1042/0264-6021:3600067 10.1111/j.1432-1033.1995.tb20780.x 10.1038/372686a0 10.1038/sj.bjp.0704565 10.1161/01.HYP.28.4.682 10.1038/sj.bjp.0702111 10.1161/hy0202.102702 10.1038/365061a0 10.1002/j.1552-4604.2002.tb06005.x 10.1073/pnas.96.24.14136 10.1161/01.CIR.103.23.2805 10.1096/fj.01-0181com 10.1111/j.1749-6632.1976.tb27927.x 10.1038/22761 10.1161/01.CIR.102.23.2873 10.1016/0006-2952(94)90134-1 10.1006/bbrc.1996.1766 10.1161/hh2401.101385 10.1006/abio.2001.5015 10.1111/j.1748-1716.1989.tb08565.x 10.1016/0014-2999(95)00487-4 10.1016/S0167-4781(02)00341-X 10.1073/pnas.86.23.9584 10.1042/bj2790129 10.1074/jbc.272.35.22330 10.1016/0014-5793(94)00773-X 10.1016/S0022-5223(99)70323-5 10.1523/JNEUROSCI.17-14-05327.1997 10.1038/37371 10.1038/sj.bjp.0701546 10.1021/jm00038a020 10.1016/0006-2952(95)00109-D 10.1042/bj3160977 10.1016/0163-7827(90)90004-5 10.1111/j.1471-4159.1993.tb03576.x 10.1073/pnas.87.5.1932 10.1002/j.1552-4604.2002.tb06004.x 10.1073/pnas.061029898 10.1016/S0165-5728(96)00181-6 10.1016/S0014-2999(02)01597-2 10.1161/01.CIR.53.4.703 10.1038/sj.bjp.0703902 10.1016/j.neuropharm.2005.11.008 10.1016/0014-2999(95)00181-J 10.1046/j.1432-1327.1999.00631.x 10.1038/sj.bjp.0702351 10.1016/0006-8993(93)91304-B |
| ContentType | Journal Article |
| Copyright | Cambridge Philosophical Society 2004 Copyright Cambridge University Press, Publishing Division Feb 2004 |
| Copyright_xml | – notice: Cambridge Philosophical Society 2004 – notice: Copyright Cambridge University Press, Publishing Division Feb 2004 |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QG 7SN 7SS C1K 7X8 |
| DOI | 10.1017/S1464793103006201 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Animal Behavior Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Entomology Abstracts Ecology Abstracts Animal Behavior Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Entomology Abstracts CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1469-185X |
| EndPage | 205 |
| ExternalDocumentID | 686878681 15005177 10_1017_S1464793103006201 BRV187 ark_67375_WNG_JHD6M6NV_1 |
| Genre | article Journal Article Review Feature |
| GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23N 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHBH AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCQX ABCUV ABEML ABITZ ABJNI ABLJU ABPVW ABQWH ABVKB ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOD ACGOF ACMXC ACPOU ACPRK ACQPF ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKSM AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BIYOS BMXJE BROTX BRXPI BY8 C45 CAG CHEAL COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZ~ H~9 IX1 J0M K48 KBYEO L7B L98 LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RCA RIG RIWAO RJQFR ROL RX1 RXW SUPJJ SV3 TAE TEORI TN5 UB1 UPT W8V W99 WBKPD WH7 WIH WIJ WIK WNSPC WOHZO WOW WQJ WRC WXI WXSBR WYISQ X6Y XG1 XOL XSW YZZ ZXP ~02 ~IA ~WT ABGDZ AEYWJ AGHNM AGQPQ AGYGG BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM PKN 7QG 7SN 7SS AAMMB AEFGJ AGXDD AIDQK AIDYY C1K 7X8 |
| ID | FETCH-LOGICAL-c4527-d1dc561420a8c35260d42e3c298f8915e39884fd5b194fcc6c78a342a025014e3 |
| IEDL.DBID | DR2 |
| ISSN | 1464-7931 |
| IngestDate | Fri Sep 05 14:47:00 EDT 2025 Wed Aug 13 08:36:06 EDT 2025 Wed Feb 19 01:36:39 EST 2025 Tue Jul 01 03:30:58 EDT 2025 Thu Apr 24 23:09:37 EDT 2025 Wed Jan 22 16:20:00 EST 2025 Sun Jun 29 03:14:25 EDT 2025 Tue Jan 21 06:22:03 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | cannabinoid signalling Cannabinoids cardiovascular protection cannabinoid receptors cardiovascular pharmacology |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4527-d1dc561420a8c35260d42e3c298f8915e39884fd5b194fcc6c78a342a025014e3 |
| Notes | ark:/67375/WNG-JHD6M6NV-1 ArticleID:BRV187 istex:F45F9861F6E404CC56C911A4A7F4DE0EE2AAD544 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 15005177 |
| PQID | 231908204 |
| PQPubID | 36769 |
| PageCount | 19 |
| ParticipantIDs | proquest_miscellaneous_71710841 proquest_journals_231908204 pubmed_primary_15005177 crossref_primary_10_1017_S1464793103006201 crossref_citationtrail_10_1017_S1464793103006201 wiley_primary_10_1017_S1464793103006201_BRV187 istex_primary_ark_67375_WNG_JHD6M6NV_1 cambridge_journals_10_1017_S1464793103006201 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20040200 2004-02 February 2004 2004-02-00 2004-Feb 20040201 |
| PublicationDateYYYYMMDD | 2004-02-01 |
| PublicationDate_xml | – month: 2 year: 2004 text: 20040200 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Cambridge, UK – name: Oxford, UK – name: England – name: Cambridge |
| PublicationTitle | Biological reviews of the Cambridge Philosophical Society |
| PublicationTitleAlternate | Biol. rev |
| PublicationYear | 2004 |
| Publisher | Cambridge University Press Blackwell Publishing Ltd |
| Publisher_xml | – name: Cambridge University Press – name: Blackwell Publishing Ltd |
| References | Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J. & Schmid, H. H. O. (2001b). Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB Journal. 15, 2171-2178. White, R., Ho, W.-S. V., Bottrill, F. E., Ford, W. R. & Hiley, C. R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. British Journal of Pharmacology. 134, 921-929. Randall, M. D., Harris, D., Kendall, D. A. & Ralevic, V. (2002). Cardiovascular effects of cannabinoids. Pharmacology and Therapeutics. 95, 191-202. Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Earth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J. P., Le Fur, G. & Casellas, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. Journal of Biological Chemistry. 272, 22330-22339. Niederhoffer, N. & Szabo, B. (1999b). Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits. British Journal of Pharmacology. 126, 1383-1386. Sugiura, T., Kodaka, T., Nakane, S., Kishimoto, S., Kondo, S. & Waku, K. (1998). Detection of an endogenous cannabiminietic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator Biochemical and Biophysical Research Communications 243, 838-843. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D. & Hogestatt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400, 452-457. Lagneux, C. & Lamontagne, D. (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. British Journal of Pharmacology. 132, 793-796. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C. & Piomelli, D. (1994). Formation and in-activation of endogenous cannabinoid anandamide in central neurons. Nature. 372, 686-691. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I. & Mechoulam, R. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences U.S.A.. 98, 3662-3665. Hillard, C.J., Manna, S., Greenberg, M.J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G. & Campbell, W. B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology and Experimental Therapeutics. 289, 1427-1433. Rinaldi-Carmona, M., Barth, F., Heauleme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C. & Le Fur, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters. 350, 240-244. Randall, M. D. & Kendall, D. A. (1997). Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. European Journal of Pharmacology. 335, 205-209. Wagner, J. A., Varga, K., Ellis, E. F, Rzigalinski, B. A., Martin, B. R. & Kunos, G. (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390, 518-521. Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A. & Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277, 1094-1097. Ellis, E. F., Moore, S. F. & Willoughby, K. A. (1995). Anandamide and Δ9-tetrahydrocannabinol dilation of cerebral arteries is blocked by indomethacin. American Journal of Physiology. 269, H1859-H1864. Fulton, D. & Quilley, J. (1998). Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. Journal of Pharmacology and Experimental Therapeutics. 286, 1146-1151. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346, 561-564. Kallner, G., Owall, A. & Franco-Cereceda, A. (1999). Myocardial outflow of calcitonin gene-related peptide in relation to metabolic stress during coronary artery bypass grafting without cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery. 117, 447-453. Glass, M. & Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. Journal of Neuroscience. 17, 5327-5333. Randall, M. D., Alexander, S. P. H., Bennett, T., Boyd, E. A., Fry, J. R., Gardiner, S. M., Kemp, P. A., Mcculloch, A. I. & Kendall, D. A. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochemical and Biophysical Research Communications. 229, 114-120. Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacological Reviews. 38, 151-178. Ishioka, N. & Bukoski, R. D. (1999). A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+ -induced relaxation. Journal of Pharmacology and Experimental Therapeutics. 289, 245-250. Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, L. (1998b). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neuroscience. 21, 521-528. Yamaguchi, F., Tokuda, M., Hatase, O. & Brenners, S. (1996). Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosome 9. Biochemical and Biophysical Research Communications. 227, 608-614. Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 34, 605-613. Childers, S. R., Sexton, T. & Roy, M. B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochemical Pharmacology. 47, 711-715. Pratt, P. F., Hillard, C. J., Edgemond, W. S. & Campbell, W. B. (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. American Journal of Physiology. 274, H375-H381. Bisogno, T., Melck, D., Bobrov, M. Y., Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L. & Di Marzo, V. (2000). N-acyldopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal. 351, 817-824. Bukoski, R. D., Bátkai, S., Járai, Z., Wang, Y., Offertaler, L., Jackson, W. F. & Kunos, G. (2002). CB1 receptor antagonist SR141716A inhibits Ca2+ -induced relaxation in CB1 receptor-deficient mice. Hypertension. 39, 251-257. Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. & Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry. 232, 54-61. Deutsch, D. G., Goligorsky, M. S., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. O., Das, S. K., Dey, S. K., Arreaza, G., Thorup, C., Stefano, G. & Moore, L. C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. Journal of Clinical Investigation. 100, 1538-1546. Molderings, G. J., Bönisch, H., Hammermann, R., Göthert, M. & Brüss, M. (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of α2- and CB1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochemistry International. 40, 157-167. Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., De Costa, B. R. & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences U.S.A.. 87, 1932-1936. Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H. & Waku, K. (1990). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. Journal of Biological Chemistry. 275, 605-612. Ralevic, V. & Kendall, D. A. (2002). Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. European Journal of Pharmacology. 444, 171-181. Chun, J., Goetzl, E. J., Hla, T., Igarashi, Y., Lynch, K. R., Moolenaar, W., Pyne, S. & Tigyi, G. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacological Reviews. 54, 265-269. Hillard, C.J. (2000). Endocannabinoids and vascular function. Journal of Pharmacology and Experimental Therapeutics. 294, 27-32. Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E. & Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. Journal of Neurochemistry. 61, 352-355. Pertwee, R. G. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opinion on Investigational Drugs. 9, 1553-1571. Ralevic, V. & Kendall, D. A. (2001). Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. European Journal of Pharmacology. 418, 117-125. Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razden, R. K., Zimmer, A. & Kunos, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences U.S.A.. 96, 14136-14141. Gifford, A. N., Tang, Y., Gatley, S 1990; 346 1997; 272 2002; 95 1994; 372 1997; 277 1999; 291 1998a; 331 1999; 283 1999; 289 1996; 384 1995; 375 2001; 41 1993; 365 1998; 274 1997; 388 2001; 132 2001; 134 2000; 129 2002; 301 1998b; 21 1997; 390 1998; 286 2001; 418 1998; 12 1998; 284 1997; 335 1995; 50 2002; 131 1989; 135 2002; 135 1971; 23 2000; 351 1992; 35 1995; 278 2001; 22 1995; 270 2001; 276 1976; 53 2000; 102 1997; 281 1995; 48 2000; 346 2000; 104 2000; 347 1990; 29 2002; 1576 1986; 29 1999; 33 1995; 269 2002; 71 2001; 38 1998; 71 1999; 117 1998; 76 1996; 118 1991; 279 1997; 238 1989; 86 1993; 603 2000; 6 1984; 26 1993; 61 2000; 9 2002; 54 2002; 55 1986; 38 1988; 34 2000; 294 1964; 86 1999; 400 1998; 359 2001; 89 1999; 126 1996; 229 2001; 103 1996; 227 1990; 87 2001; 294 1996; 28 2002; 42 2000; 57 2002; 40 1997; 100 2002; 100 1973; 49 1991; 40 1997; 17 1994; 37 1999; 96 1998a; 125 1995; 287 1976; 281 1998; 243 1990; 255 1998; 54 2001; 98 2002; 39 1995; 92 2002; 30 1994; 350 2001a; 360 1999b; 126 1992; 105 1999; 264 1999a; 126 1994; 47 2000; 275 1995; 232 2003; 72 1998; 1394 2003; 134 1998b; 125 1997; 72 1997; 121 2002; 444 1997; 122 1996; 271 2001b; 15 2000; 141 1999; 276 1996; 278 1990; 275 2003; 63 1996; 316 e_1_2_1_119_1 Rinaldi‐Carmona M. (e_1_2_1_104_1) 1998; 284 e_1_2_1_111_1 e_1_2_1_81_1 e_1_2_1_134_1 e_1_2_1_115_1 e_1_2_1_20_1 e_1_2_1_66_1 e_1_2_1_89_1 e_1_2_1_24_1 e_1_2_1_43_1 e_1_2_1_85_1 Devane W. A. (e_1_2_1_22_1) 1988; 34 Slipetz D. M. (e_1_2_1_114_1) 1995; 48 e_1_2_1_92_1 e_1_2_1_103_1 e_1_2_1_122_1 e_1_2_1_107_1 e_1_2_1_126_1 e_1_2_1_77_1 e_1_2_1_8_1 Gebremedhin D. (e_1_2_1_42_1) 1999; 276 e_1_2_1_12_1 Dewey W. L. (e_1_2_1_23_1) 1986; 38 e_1_2_1_35_1 e_1_2_1_50_1 e_1_2_1_96_1 e_1_2_1_4_1 e_1_2_1_110_1 e_1_2_1_16_1 e_1_2_1_39_1 e_1_2_1_58_1 e_1_2_1_82_1 Mu J. (e_1_2_1_84_1) 1999; 291 e_1_2_1_133_1 Ishioka N. (e_1_2_1_62_1) 1999; 289 e_1_2_1_118_1 Rinaldi‐Carmona M. (e_1_2_1_105_1) 1996; 278 e_1_2_1_40_1 e_1_2_1_67_1 e_1_2_1_121_1 e_1_2_1_21_1 e_1_2_1_63_1 e_1_2_1_86_1 Lake K. D. (e_1_2_1_71_1) 1997; 281 e_1_2_1_25_1 Ellis E. F. (e_1_2_1_31_1) 1995; 269 Gifford A. N. (e_1_2_1_44_1) 1997; 238 e_1_2_1_29_1 e_1_2_1_93_1 e_1_2_1_125_1 e_1_2_1_70_1 e_1_2_1_102_1 e_1_2_1_129_1 e_1_2_1_106_1 e_1_2_1_7_1 e_1_2_1_78_1 e_1_2_1_3_1 e_1_2_1_13_1 e_1_2_1_51_1 e_1_2_1_97_1 e_1_2_1_132_1 e_1_2_1_32_1 e_1_2_1_74_1 e_1_2_1_17_1 Gómez del Pulgar T. (e_1_2_1_47_1) 2000; 347 e_1_2_1_36_1 Di Marzo V. (e_1_2_1_28_1) 1994; 372 Ward S.J. (e_1_2_1_128_1) 1990; 255 e_1_2_1_60_1 e_1_2_1_113_1 e_1_2_1_117_1 e_1_2_1_41_1 e_1_2_1_87_1 e_1_2_1_68_1 e_1_2_1_120_1 e_1_2_1_45_1 e_1_2_1_83_1 Howlett A. C. (e_1_2_1_57_1) 1984; 26 e_1_2_1_64_1 e_1_2_1_49_1 Bisogno T. (e_1_2_1_10_1) 2000; 351 e_1_2_1_26_1 e_1_2_1_109_1 Hardman H. F. (e_1_2_1_52_1) 1971; 23 e_1_2_1_101_1 e_1_2_1_124_1 Felder C. C. (e_1_2_1_34_1) 1995; 48 e_1_2_1_90_1 Howlett A. C. (e_1_2_1_59_1) 1986; 29 e_1_2_1_56_1 e_1_2_1_79_1 e_1_2_1_98_1 e_1_2_1_6_1 e_1_2_1_131_1 e_1_2_1_33_1 e_1_2_1_75_1 e_1_2_1_94_1 e_1_2_1_2_1 Hillard C.J. (e_1_2_1_55_1) 1999; 289 e_1_2_1_14_1 e_1_2_1_37_1 e_1_2_1_18_1 e_1_2_1_80_1 e_1_2_1_112_1 e_1_2_1_116_1 Liu J. (e_1_2_1_73_1) 2000; 346 e_1_2_1_88_1 e_1_2_1_46_1 e_1_2_1_61_1 e_1_2_1_27_1 Fulton D. (e_1_2_1_38_1) 1998; 286 e_1_2_1_69_1 Gonsiorek W. (e_1_2_1_48_1) 2000; 57 e_1_2_1_108_1 e_1_2_1_100_1 e_1_2_1_91_1 e_1_2_1_123_1 e_1_2_1_127_1 Hillard C.J. (e_1_2_1_54_1) 2000; 294 e_1_2_1_30_1 e_1_2_1_76_1 e_1_2_1_5_1 Jones R. T. (e_1_2_1_65_1) 2002; 42 e_1_2_1_99_1 e_1_2_1_72_1 e_1_2_1_11_1 e_1_2_1_53_1 e_1_2_1_95_1 e_1_2_1_130_1 e_1_2_1_15_1 e_1_2_1_9_1 e_1_2_1_19_1 |
| References_xml | – reference: Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R. & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews. 54, 161-202. – reference: Gómez del Pulgar, T., Velasco, G. & Guzmán, M. (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochemical Journal. 347, 369-373. – reference: Pertwee, R. G., Stevenson, L. A., Elrick, D. B., Mechoulam, R. & Corbett, A. D. (1992). Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. British Journal of Pharmacology. 105, 980-984. – reference: Sugiura, T., Kodaka, T., Nakane, S., Kishimoto, S., Kondo, S. & Waku, K. (1998). Detection of an endogenous cannabiminietic molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator Biochemical and Biophysical Research Communications 243, 838-843. – reference: Gill, E. W. (1976). The effects of cannabinoids and other CNS depressants on cell membrane models. Annals of the New York Academy of Sciences. 281, 151-161. – reference: Glass, M. & Felder, C. C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. Journal of Neuroscience. 17, 5327-5333. – reference: Schmid, H. H. O., Schmid, P. C. & Natarajan, V. (1990). N-acylated glycerophospholipids and their derivatives. Progress in Lipid Research. 29, 1-43. – reference: Gaoni, Y. & Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of haschish. Journal of the American Chemical Society. 86, 1646-1648. – reference: Ford, W. R., Honan, S. A., White, R. & Hiley, C. R. (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. British Journal of Pharmacology. 135, 1191-1198. – reference: Lagneux, C. & Lamontagne, D. (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. British Journal of Pharmacology. 132, 793-796. – reference: Gérard, C. M., Mollereau, C., Vassart, G. & Parmentier, M. (1991). Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochemical Journal. 279, 129-134. – reference: Pacheco, M. A., Ward, S. J. & Guilders, S. R. (1993). Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Research. 603, 102-110. – reference: D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., Casiano, F. M., Beglin, N. C., Chippari, S. M., Grego, J. D., Kullnig, R. K. & Daley, G. T. (1992). Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective (aminoalkyl)indole agonists of the cannabinoid receptor. Journal of Medicinal Chemistry. 35, 124-135. – reference: Aikawa, R., Nawano, M., Gu, Y., Katagiri, H., Asano, T., Zhu, W., Nagai, R. & Komuro, I. (2000). Insulin prevents cardio-myocytes from oxidative stress-induced apoptosis through activation of PI3 kinase/Akt. Circulation. 102, 2873-2879. – reference: Childers, S. R., Sexton, T. & Roy, M. B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochemical Pharmacology. 47, 711-715. – reference: Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C. & Piomelli, D. (1994). Formation and in-activation of endogenous cannabinoid anandamide in central neurons. Nature. 372, 686-691. – reference: Varga, K., Lake, K. D., Huangfu, D., Guyenet, P. G. & Kunos, G. (1996). Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension. 28, 682-686. – reference: Randall, M. D., Alexander, S. P. H., Bennett, T., Boyd, E. A., Fry, J. R., Gardiner, S. M., Kemp, P. A., Mcculloch, A. I. & Kendall, D. A. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochemical and Biophysical Research Communications. 229, 114-120. – reference: Niederhoffer, N. & Szabo, B. (1999a). Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. British Journal of Pharmacology. 126, 457-466. – reference: Niederhoffer, N. & Szabo, B. (1999b). Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits. British Journal of Pharmacology. 126, 1383-1386. – reference: Rinaldi-Carmona, M., Barth, F., Heauleme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Neliat, G., Caput, D., Ferrara, P., Soubrie, P., Breliere, J. C. & Le Fur, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters. 350, 240-244. – reference: Mechoulam, R., Fride, E. & Di Marzo, B. (1998). Endocannabinoids. European Journal of Pharmacology. 359, 1-18. – reference: Graham, J. D. P. & Li, D. M. F. (1973). Cardiovascular and respiratory effects of cannabis in the cat and rat. British Journal of Pharmacology. 49, 1-10. – reference: Sidney, S. (2002). Cardiovascular consequences of marijuana use. Journal of Clinical Pharmacology. 42 (Suppl. 11), 64S-70S. – reference: Bayewitch, M., Avidor-Reiss, T., Levy, R., Barg, J., Mechoulam, R. & Vogel, Z. (1995). The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Letters. 375, 143-147. – reference: Wagner, J. A., Varga, K., Járai, Z. & Kunos, G. (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33, 429-434. – reference: Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A. & Piomelli, D. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277, 1094-1097. – reference: Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S. & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 34, 605-613. – reference: Coutts, A. A., Brewster, N., Ingram, T., Razdan, R. K. & Pertwee, R. G. (2000). Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. British Journal of Pharmacology. 129, 645-652. – reference: Wagner, J. A., Varga, K., Ellis, E. F, Rzigalinski, B. A., Martin, B. R. & Kunos, G. (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390, 518-521. – reference: Molderings, G. J., Bönisch, H., Hammermann, R., Göthert, M. & Brüss, M. (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of α2- and CB1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochemistry International. 40, 157-167. – reference: Abadji, V., Lin, S., Taha, G., Griffin, G., Stevenson, L. A., Pertwee, R. G. & Makriyannis, A. (1994). (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. Journal of Medicinal Chemistry. 37, 1889-1893. – reference: Hillard, C.J., Manna, S., Greenberg, M.J., DiCamelli, R., Ross, R. A., Stevenson, L. A., Murphy, V., Pertwee, R. G. & Campbell, W. B. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). Journal of Pharmacology and Experimental Therapeutics. 289, 1427-1433. – reference: Ho, B. Y., Stadnicka, A., Prather, P. L., Buckley, A. R., Current, L. L., Bosnjak, Z. J. & Kwok, W. M. (2000). Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology. 141, 1675-1685. – reference: Varga, K., Lake, K. D., Martin, B. R. & Kunos, G. (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. European Journal of Pharmacology. 278, 279-283. – reference: Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A. L. & Mitchell, R. L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Molecular Pharmacology. 48, 443-450. – reference: Gebremedhin, D., Lange, A. R., Campbell, W. B., Hillard, C. J. & Harder, D. R. (1999). Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. American Journal of Physiology. 276, H2085-H2093. – reference: Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A. & Pertwee, R. G. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. British Journal of Pharmacology. 126, 665-672. – reference: Howlett, A. C., Qualy, J. M. & Khachatrian, L. L. (1986). Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Molecular Pharmacology. 29, 307-313. – reference: Schmid, P. C., Schwartz, K. D., Smith, C. N., Krebsbach, R. J., Berdyshev, E. V. & Schmid, H. H. O. (2000). A sensitive endocannabinoid assay. The simultaneous analysis of N-acylethanol-amines and 2-monoacylglycerols. Chemistry and Physics of Lipids. 104, 185-191. – reference: Hardman, H. F., Domino, E. F. & Seevers, M. H. (1971). General pharmacological actions of some synthetic tetrahydrocannabinol derivatives. Pharmacological Reviews. 23, 295-315. – reference: Shire, D., Carillon, C., Kaghad, M., Calandra, B., Rinaldi-Carmona, M., Le Fur, G., Caput, D. & Ferrara, P. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. Journal of Biological Chemistry. 270, 3726-3731. – reference: White, R., Ho, W.-S. V., Bottrill, F. E., Ford, W. R. & Hiley, C. R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. British Journal of Pharmacology. 134, 921-929. – reference: Shohami, E., Gallily, R., Mechoulam, R., Bass, R. & Ben-Hur, T. (1997). Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Journal of Neuroimmunology. 72, 169-177. – reference: Pestonjamasp, V. K. & Burstein, S. H. (1998). Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochimica Biophysica Acta. 1394, 249-260. – reference: Howlett, A. C. & Fleming, R. M. (1984). Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology. 26, 532-538. – reference: Hillard, C.J. (2000). Endocannabinoids and vascular function. Journal of Pharmacology and Experimental Therapeutics. 294, 27-32. – reference: Barg, J., Fride, E., Hanus, L., Levy, R., Matus-Leibovitch, N., Heldman, E., Bayewitch, M., Mechoulam, R. & Vogel, Z. (1995). Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. European Journal of Pharmacology. 287, 145-152. – reference: Bukoski, R. D., Bátkai, S., Járai, Z., Wang, Y., Offertaler, L., Jackson, W. F. & Kunos, G. (2002). CB1 receptor antagonist SR141716A inhibits Ca2+ -induced relaxation in CB1 receptor-deficient mice. Hypertension. 39, 251-257. – reference: Chun, J., Goetzl, E. J., Hla, T., Igarashi, Y., Lynch, K. R., Moolenaar, W., Pyne, S. & Tigyi, G. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacological Reviews. 54, 265-269. – reference: Gifford, A. N., Tang, Y., Gatley, S. J., Volkow, N. D., Lan, R. & Makriyannis, A. (1997). Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neuroscience Letters. 238, 84-86. – reference: Munro, S., Thomas, K. L. & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365, 61-65. – reference: Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D. & Leon, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences U.S.A.. 92, 3376-3380. – reference: White, R. & Hiley, C. R. (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. British Journal of Pharmacology. 122, 1573-1584. – reference: Wagner, J. A., Varga, K. & Kunos, G. (1998). Cardiovascular actions of cannabinoids and their generation during shock. Journal of Molecular Medicine. 76, 824-836. – reference: Ishac, E. J., Jiang, L., Lake, K. D., Varga, K., Abood, M. E. & Kunos, G. (1996). Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. British Journal of Pharmacology. 118, 2023-2028. – reference: Galiègue, S., Mary, S., Marchand, J., Dussossoy, D., Carrière, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G. & Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry. 232, 54-61. – reference: Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Earth, F., Calandra, B., Pecceu, F., Lupker, J., Maffrand, J. P., Le Fur, G. & Casellas, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. Journal of Biological Chemistry. 272, 22330-22339. – reference: Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., De Costa, B. R. & Rice, K. C. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences U.S.A.. 87, 1932-1936. – reference: Moesgaard, B., Petersen, G., Mortensen, S. A. & Hansen, H. S. (2002). Substantial species differences in relation to formation and degradation of N-acyl-ethanolamine phospholipids in heart tissue: an enzyme activity study. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology. 131, 475-482. – reference: Fukushima, N., Ishii, I., Contos, J. J. A., Weiner, J. A. & Chun, J. (2001). Lysophospholipid receptors. Annual Reviews of Pharmacology and Toxicology. 41, 507-534. – reference: Slipetz, D. M., O'Neill, G. P., Favreau, L., Dufresne, C., Gallant, M., Gareau, Y., Guay, D., Labelle, M. & Metters, K. M. (1995). Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Molecular Pharmacology. 48, 352-361. – reference: Jones, R. T. (2002). Cardiovascular effects of marijuana. Journal of Clinical Pharmacology. 42 (Suppl. 11), 58S-63S. – reference: Bayewitch, M., Rhee, M. H., Avidor-Reiss, T., Breuer, A., Mechoulam, R. & Vogel, Z. (1996). (-)-Δ9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. Journal of Biological Chemistry. 271, 9902-9905. – reference: Kallner, G., Owall, A. & Franco-Cereceda, A. (1999). Myocardial outflow of calcitonin gene-related peptide in relation to metabolic stress during coronary artery bypass grafting without cardiopulmonary bypass. Journal of Thoracic and Cardiovascular Surgery. 117, 447-453. – reference: Rinaldi-Carmona, M., Calandra, B., Shire, D., Bouaboula, M., Oustric, D., Barth, F., Casellas, P., Ferrara, P. & Le Fur, G. (1996). Characterization of two cloned human CB1 isoforms. Journal of Pharmacology and Experimental Therapeutics. 278, 871-878. – reference: Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J. & Schmid, H. H. O. (2001b). Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB Journal. 15, 2171-2178. – reference: Showalter, V. M., Compton, D. R., Martin, B. R. & Abood, M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. Journal of Pharmacology and Experimental Therapeutics. 278, 989-999. – reference: Liu, J., Gao, B., Mirshahi, F., Sanyal, A.J., Khanolkar, A. D., Makriyannis, A. & Kunos, G. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochemical Journal. 346, 835-840. – reference: Feigenbaum, J. J., Bergmann, F., Richmond, S. A., Mechoulam, R., Nadler, V., Kloog, Y. & Sokolovsky, M. (1989). Nonpsychotropic cannabinoid acts as a functional N-methyl-d-aspartate receptor blocker. Proceedings of the National Academy of Sciences U.S.A.. 86, 9584-9587. – reference: Joyeux, M., Arnaud, C., Godin-Ribuot, D., Demenge, P., Lamontagne, D. & Ribuot, C. (2002). Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovascular Research. 55, 619-625. – reference: Di Marzo, V., Breivogel, C. S., Tao, Q., Bridgen, D. T., Razdan, R. K., Zimmer, A. M., Zimmer, A. & Martin, B. R. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1 non-CB2 receptor-mediated actions of anandamide in mouse brain. Journal of Neurochemistry. 57, 2434-2444. – reference: Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barg, J. & Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 50, 83-90. – reference: Edgemond, W. S., Hillard, C. J., Falck, J. R., Kearn, C. S. & Campbell, W. B. (1998). Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Molecular Pharmacology. 54, 180-188. – reference: White, R. & Hiley, C. R. (1998b). The actions of the cannabinoid receptor antagonist, SR141716A, in the rat isolated mesenteric artery. British Journal of Pharmacology. 125, 689-696. – reference: Yamaguchi, F., Tokuda, M., Hatase, O. & Brenners, S. (1996). Molecular cloning of the novel human G protein-coupled receptor (GPCR) gene mapped on chromosome 9. Biochemical and Biophysical Research Communications. 227, 608-614. – reference: Porter, A. C., Sauer, J. M., Knierman, M. D., Becker, G. W., Berna, M.J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B. & Felder, C. C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. Journal of Pharmacology and Experimental Therapeutics. 301, 1020-1024. – reference: Maccarrone, M., Bari, M., Battista, N. & Finazzi-Agro, A. (2002). Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood. 100, 4040-4048. – reference: Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D. & Hogestatt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400, 452-457. – reference: Ellis, E. F., Moore, S. F. & Willoughby, K. A. (1995). Anandamide and Δ9-tetrahydrocannabinol dilation of cerebral arteries is blocked by indomethacin. American Journal of Physiology. 269, H1859-H1864. – reference: Mu, J., Zhuang, S. Y., Kirby, M. T., Hampson, R. E. & Deadwyler, S. A. (1999). Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. Journal of Pharmacology and Experimental Therapeutics. 291, 893-902. – reference: Pertwee, R. G. (2000). Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opinion on Investigational Drugs. 9, 1553-1571. – reference: Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I. & Mechoulam, R. (2001). 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proceedings of the National Academy of Sciences U.S.A.. 98, 3662-3665. – reference: Guzmán, M., Galve-Roperh, I. & Sánchez, C. (2001). Ceramide, a new second messenger of cannabinoid action. Trends in Pharmacological Sciences. 22, 19-22. – reference: Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H. & Waku, K. (1990). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. Journal of Biological Chemistry. 275, 605-612. – reference: Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E. & Mechoulam, R. (1993). Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. Journal of Neurochemistry. 61, 352-355. – reference: Schmid, P. C., Krebsbach, R. J., Perry, S. R., Dettmer, T. M., Maasson, J. L. & Schmid, H. H. O. (1995). Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Letters. 375, 117-120. – reference: Offertáler, L., Mo, F.-M., Bátkai, S., Liu, J., Begg, M., Razdan, R. K., Martin, B. R., Bukoski, R. D. & Kunos, G. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology. 63, 699-705. – reference: Wagner, J. A., Hu, K., Karcher, J., Bauersachs, J., Shäfer, A., Laser, M., Han, H. & Ertl, G. (2003). CB1 cannabinoid receptor antagonism promoted remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. British Journal of Pharmacology. 134, 1251-1258. – reference: Dewey, W. L. (1986). Cannabinoid pharmacology. Pharmacological Reviews. 38, 151-178. – reference: Di Marzo, V., Bisogno, T., De Petrocellis, L., Melck, D., Orlando, P., Wagner, J. A. & Kunos, G. (1999). Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. European Journal of Biochemistry. 264, 258-267. – reference: Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A. & Gilula, N. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384, 83-87. – reference: Lake, K. D., Compton, D. R., Varga, K., Martin, B. R. & Kunos, G. (1997). Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors Journal of Pharmacology and Experimental Therapeutics 281, 1030-1037. – reference: Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J. F., Beslot, F., Bohme, G. A., Imperato, A., Pedrazzini, T., Roques, B. P., Vassart, G., Fratta, W. & Parmentier, M. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283, 401-404. – reference: Randall, M. D., Harris, D., Kendall, D. A. & Ralevic, V. (2002). Cardiovascular effects of cannabinoids. Pharmacology and Therapeutics. 95, 191-202. – reference: Rhee, M. H., Bayewitch, M., Avidor-Reiss, T., Levy, R. & Vogel, Z. (1998). Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. Journal of Neurochemistry. 71, 1525-1534. – reference: Varga, K., Wagner, J. A., Bridgen, T. D. & Kunos, G. (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB Journal. 12, 1035-1044. – reference: Di Marzo, V., Melck, D., Bisogno, T. & De Petrocellis, L. (1998b). Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neuroscience. 21, 521-528. – reference: Fulton, D. & Quilley, J. (1998). Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. Journal of Pharmacology and Experimental Therapeutics. 286, 1146-1151. – reference: Stella, N., Schweitzer, P. & Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388, 773-778. – reference: Gonsiorek, W., Lunn, C., Fan, X., Narula, S., Lundell, D. & Hipkin, R. W. (2000). Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Molecular Pharmacology. 57, 1045-1050. – reference: Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. (1998a). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophillike cells: connections with anandamide. Biochemical Journal. 331, 15-19. – reference: Ralevic, V. & Kendall, D. A. (2002). Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. European Journal of Pharmacology. 444, 171-181. – reference: White, R. & Hiley, C. R. (1998a). The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. British Journal of Pharmacology. 125, 533-541. – reference: De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agro, A. & Di Marzo, V. (2001). The activity of anandamide at vanilloid VRI receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. Journal of Biological Chemistry. 276, 12856-12863. – reference: Brown, S. M., Wager-Miller, J. & Mackie, K. (2002). Cloning and molecular characterization of the rat CB2 cannabinoid receptor. Biochimica Biophysica Acta. 1576, 255-264. – reference: Deutsch, D. G., Goligorsky, M. S., Schmid, P. C., Krebsbach, R. J., Schmid, H. H. O., Das, S. K., Dey, S. K., Arreaza, G., Thorup, C., Stefano, G. & Moore, L. C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. Journal of Clinical Investigation. 100, 1538-1546. – reference: Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. (1996). Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochemical Journal. 316, 977-984. – reference: Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. (2000). Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. Journal of Biological Chemistry. 275, 31938-31945. – reference: Ralevic, V. & Kendall, D. A. (2001). Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. European Journal of Pharmacology. 418, 117-125. – reference: Wang, Y., Liu, Y., Ito, Y., Hashiguchi, T., Kitajima, I., Yamakuchi, M., Shimizu, H., Matsuo, S., Imaizumi, H. & Maruyama, I. (2001). Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Analytical Biochemistry. 294, 73-82. – reference: Franco-Cereceda, A., Saria, A. & Lundberg, J. M. (1989). Differential release of calcitonin gene-related peptide and neuropeptide Y from the isolated heart by capsaicin, ischaemia, nicotine, bradykinin and ouabain. Acta Physiologica Scandinavica. 135, 173-187. – reference: Ishioka, N. & Bukoski, R. D. (1999). A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent Ca2+ -induced relaxation. Journal of Pharmacology and Experimental Therapeutics. 289, 245-250. – reference: Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346, 561-564. – reference: Ward, S.J., Mastriani, D., Casiano, F. & Arnold, R. (1990). Pravadoline: profile in isolated tissue preparations. Journal of Pharmacology and Experimental Therapeutics. 255, 1230-1239. – reference: Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J. M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Breliere, J. C. & Le Fur, G. L. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. Journal of Pharmacology and Experimental Therapeutics. 284, 644-650. – reference: Berdyshev, E. V., Schmid, P. C., Krebsbach, R. J., Hillard, C. J., Huang, C., Chen, N., Dong, Z. & Schmid, H. H. O. (2001a). Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochemical Journal. 360, 67-75. – reference: Knoller, N., Levi, L., Shoshan, I., Reichenthal, E., Razon, N., Rappaport, Z. H. & Biegon, A. (2002). Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Critical Care Medicine. 30, 548-554. – reference: Bouchard, J. F., Lépicier, P. & Lamontagne, D. (2003). Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sciences. 72, 1859-1870. – reference: Plane, F., Holland, M., Waldron, G. J., Garland, C. J. & Boyle, J. P. (1997). Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries. British Journal of Pharmacology. 121, 1509-1511. – reference: Randall, M. D. & Kendall, D. A. (1997). Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. European Journal of Pharmacology. 335, 205-209. – reference: Pratt, P. F., Hillard, C. J., Edgemond, W. S. & Campbell, W. B. (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. American Journal of Physiology. 274, H375-H381. – reference: Bisogno, T., Melck, D., Bobrov, M. Y., Gretskaya, N. M., Bezuglov, V. V., De Petrocellis, L. & Di Marzo, V. (2000). N-acyldopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal. 351, 817-824. – reference: Kanakis, C., Pouget, J. M. & Rosen, K. M. (1976). The effects of Δ9-THC (cannabis) on cardiac performance with or without beta blockade. Circulation. 53, 703-709. – reference: Wagner, J. A., Hu, K., Bauersachs, J., Karcher, J., Wiesler, M., Goparaju, S. K., Kunos, G. & Ertl, G. (2001). Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. Journal of the American College of Cardiologists. 38, 2048-2054. – reference: Martin, B. R., Compton, D. R., Thomas, B. F., Prescott, W. R., Little, P. J., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R. & Ward, S. J. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacology Biochemistry Behavior. 40, 471-478. – reference: Galve-Roperh, I., Sánchez, C., Córtes, M. L., Del Pulgar, T. G., Izquierdo, M. & Guzmán, M. (2000). Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine. 6, 313-319. – reference: Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B. & Muller, J. E. (2001). Triggering myocardial infarction by marijuana. Circulation. 103, 2805-2809. – reference: Járai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razden, R. K., Zimmer, A. & Kunos, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences U.S.A.. 96, 14136-14141. – reference: Mombouli, J. V., Schaeffer, G., Holzmann, S., Kostner, G. M. & Graier, W. F. (1999). Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. British Journal of Pharmacology. 126, 1593-1600. – reference: Huang, S. M., Bisogno, T., Petros, T.J., Chang, S. Y., Zavitsanos, P. A., Zipkin, R. E., Sivakumar, R., Coop, A., Maeda, D. Y., De Petrocellis, L., Burstein, S., Di Marzo, V. & Walker, J. M. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. Journal of Biological Chemistry. 276, 42639-42644. – reference: Ralevic, V., Kendall, D. A., Randall, M. D. & Smart, D. (2002). Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sciences. 71, 2577-2594. – reference: Jonassen, A. K., Sack, M. N., Mjos, O. D. & Yellon, D. M. (2001). Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circulation Research. 89, 1191-1198. – volume: 47 start-page: 711 year: 1994 end-page: 715 article-title: Effects of anandamide on cannabinoid receptors in rat brain membranes publication-title: Biochemical Pharmacology – volume: 331 start-page: 15 year: 1998a end-page: 19 article-title: The novel endogenous cannabinoid 2‐arachidonoylglycerol is inactivated by neuronal‐ and basophillike cells: connections with anandamide publication-title: Biochemical Journal – volume: 55 start-page: 619 year: 2002 end-page: 625 article-title: Endocannabinoids are implicated in the infarct size‐reducing effect conferred by heat stress preconditioning in isolated rat hearts publication-title: Cardiovascular Research – volume: 365 start-page: 61 year: 1993 end-page: 65 article-title: Molecular characterization of a peripheral receptor for cannabinoids publication-title: Nature – volume: 134 start-page: 1251 year: 2003 end-page: 1258 article-title: CB cannabinoid receptor antagonism promoted remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction publication-title: British Journal of Pharmacology – volume: 131 start-page: 475 year: 2002 end-page: 482 article-title: Substantial species differences in relation to formation and degradation of ‐acyl‐ethanolamine phospholipids in heart tissue: an enzyme activity study publication-title: Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology – volume: 359 start-page: 1 year: 1998 end-page: 18 article-title: Endocannabinoids publication-title: European Journal of Pharmacology – volume: 23 start-page: 295 year: 1971 end-page: 315 article-title: General pharmacological actions of some synthetic tetrahydrocannabinol derivatives publication-title: Pharmacological Reviews – volume: 278 start-page: 989 year: 1996 end-page: 999 article-title: Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB ): identification of cannabinoid receptor subtype selective ligands publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 126 start-page: 1383 year: 1999b end-page: 1386 article-title: Involvement of CB cannabinoid receptors in the EDHF‐dependent vasorelaxation in rabbits publication-title: British Journal of Pharmacology – volume: 49 start-page: 1 year: 1973 end-page: 10 article-title: Cardiovascular and respiratory effects of cannabis in the cat and rat publication-title: British Journal of Pharmacology – volume: 135 start-page: 173 year: 1989 end-page: 187 article-title: Differential release of calcitonin gene‐related peptide and neuropeptide Y from the isolated heart by capsaicin, ischaemia, nicotine, bradykinin and ouabain publication-title: Acta Physiologica Scandinavica – volume: 100 start-page: 1538 year: 1997 end-page: 1546 article-title: Production and physiological actions of anandamide in the vasculature of the rat kidney publication-title: Journal of Clinical Investigation – volume: 283 start-page: 401 year: 1999 end-page: 404 article-title: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB receptor knockout mice publication-title: Science – volume: 390 start-page: 518 year: 1997 end-page: 521 article-title: Activation of peripheral CB cannabinoid receptors in haemorrhagic shock publication-title: Nature – volume: 105 start-page: 980 year: 1992 end-page: 984 article-title: Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea‐pig small intestine publication-title: British Journal of Pharmacology – volume: 294 start-page: 27 year: 2000 end-page: 32 article-title: Endocannabinoids and vascular function publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 351 start-page: 817 year: 2000 end-page: 824 article-title: ‐acyldopamines: novel synthetic CB cannabinoid‐receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity and publication-title: Biochemical Journal – volume: 72 start-page: 169 year: 1997 end-page: 177 article-title: Cytokine production in the brain following closed head injury: dexanabinol (HU‐211) is a novel TNF‐alpha inhibitor and an effective neuroprotectant publication-title: Journal of Neuroimmunology – volume: 287 start-page: 145 year: 1995 end-page: 152 article-title: Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides publication-title: European Journal of Pharmacology – volume: 278 start-page: 871 year: 1996 end-page: 878 article-title: Characterization of two cloned human CB isoforms publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 40 start-page: 471 year: 1991 end-page: 478 article-title: Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs publication-title: Pharmacology Biochemistry Behavior – volume: 9 start-page: 1553 year: 2000 end-page: 1571 article-title: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development publication-title: Expert Opinion on Investigational Drugs – volume: 89 start-page: 1191 year: 2001 end-page: 1198 article-title: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell‐survival signaling publication-title: Circulation Research – volume: 125 start-page: 689 year: 1998b end-page: 696 article-title: The actions of the cannabinoid receptor antagonist, SR141716A, in the rat isolated mesenteric artery publication-title: British Journal of Pharmacology – volume: 92 start-page: 3376 year: 1995 end-page: 3380 article-title: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide publication-title: Proceedings of the National Academy of Sciences U.S.A. – volume: 275 start-page: 605 year: 1990 end-page: 612 article-title: Evidence that 2‐arachidonoylglycerol but not ‐palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL‐60 cells publication-title: Journal of Biological Chemistry – volume: 54 start-page: 265 year: 2002 end-page: 269 article-title: International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature publication-title: Pharmacological Reviews – volume: 388 start-page: 773 year: 1997 end-page: 778 article-title: A second endogenous cannabinoid that modulates long‐term potentiation publication-title: Nature – volume: 42 start-page: 64S issue: Suppl. 11 year: 2002 end-page: 70S article-title: Cardiovascular consequences of marijuana use publication-title: Journal of Clinical Pharmacology – volume: 76 start-page: 824 year: 1998 end-page: 836 article-title: Cardiovascular actions of cannabinoids and their generation during shock publication-title: Journal of Molecular Medicine – volume: 289 start-page: 1427 year: 1999 end-page: 1433 article-title: Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 301 start-page: 1020 year: 2002 end-page: 1024 article-title: Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 135 start-page: 1191 year: 2002 end-page: 1198 article-title: Evidence of a novel site mediating anandamide‐induced negative inotropic and coronary vasodilatator responses in rat isolated hearts publication-title: British Journal of Pharmacology – volume: 291 start-page: 893 year: 1999 end-page: 902 article-title: Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 281 start-page: 1030 year: 1997 end-page: 1037 article-title: Cannabinoid‐induced hypotension and bradycardia in rats is mediated by CB ‐like cannabinoid receptors publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 132 start-page: 793 year: 2001 end-page: 796 article-title: Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide publication-title: British Journal of Pharmacology – volume: 54 start-page: 161 year: 2002 end-page: 202 article-title: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors publication-title: Pharmacological Reviews – volume: 335 start-page: 205 year: 1997 end-page: 209 article-title: Involvement of a cannabinoid in endothelium‐derived hyperpolarizing factor‐mediated coronary vasorelaxation publication-title: European Journal of Pharmacology – volume: 38 start-page: 2048 year: 2001 end-page: 2054 article-title: Endogenous cannabinoids mediate hypotension after experimental myocardial infarction publication-title: Journal of the American College of Cardiologists – volume: 1394 start-page: 249 year: 1998 end-page: 260 article-title: Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system publication-title: Biochimica Biophysica Acta – volume: 6 start-page: 313 year: 2000 end-page: 319 article-title: Anti‐tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal‐regulated kinase activation publication-title: Nature Medicine – volume: 346 start-page: 835 year: 2000 end-page: 840 article-title: Functional CB cannabinoid receptors in human vascular endothelial cells publication-title: Biochemical Journal – volume: 289 start-page: 245 year: 1999 end-page: 250 article-title: A role for ‐arachidonylethanolamine (anandamide) as the mediator of sensory nerve‐dependent Ca ‐induced relaxation publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 270 start-page: 3726 year: 1995 end-page: 3731 article-title: An amino‐terminal variant of the central cannabinoid receptor resulting from alternative splicing publication-title: Journal of Biological Chemistry – volume: 17 start-page: 5327 year: 1997 end-page: 5333 article-title: Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a G linkage to the CB1 receptor publication-title: Journal of Neuroscience – volume: 96 start-page: 14136 year: 1999 end-page: 14141 article-title: Cannabinoid‐induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors publication-title: Proceedings of the National Academy of Sciences U.S.A. – volume: 255 start-page: 1230 year: 1990 end-page: 1239 article-title: Pravadoline: profile in isolated tissue preparations publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 274 start-page: H375 year: 1998 end-page: H381 article-title: ‐arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor publication-title: American Journal of Physiology – volume: 48 start-page: 352 year: 1995 end-page: 361 article-title: Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase publication-title: Molecular Pharmacology – volume: 87 start-page: 1932 year: 1990 end-page: 1936 article-title: Cannabinoid receptor localization in brain publication-title: Proceedings of the National Academy of Sciences U.S.A. – volume: 275 start-page: 31938 year: 2000 end-page: 31945 article-title: Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors publication-title: Journal of Biological Chemistry – volume: 232 start-page: 54 year: 1995 end-page: 61 article-title: Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations publication-title: European Journal of Biochemistry – volume: 126 start-page: 665 year: 1999 end-page: 672 article-title: Agonist‐inverse agonist characterization at CB and CB cannabinoid receptors of L759633, L759656, and AM630 publication-title: British Journal of Pharmacology – volume: 98 start-page: 3662 year: 2001 end-page: 3665 article-title: 2‐arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB receptor publication-title: Proceedings of the National Academy of Sciences U.S.A. – volume: 86 start-page: 9584 year: 1989 end-page: 9587 article-title: Nonpsychotropic cannabinoid acts as a functional ‐methyl‐d‐aspartate receptor blocker publication-title: Proceedings of the National Academy of Sciences U.S.A. – volume: 276 start-page: 12856 year: 2001 end-page: 12863 article-title: The activity of anandamide at vanilloid VRI receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism publication-title: Journal of Biological Chemistry – volume: 38 start-page: 151 year: 1986 end-page: 178 article-title: Cannabinoid pharmacology publication-title: Pharmacological Reviews – volume: 103 start-page: 2805 year: 2001 end-page: 2809 article-title: Triggering myocardial infarction by marijuana publication-title: Circulation – volume: 360 start-page: 67 year: 2001a end-page: 75 article-title: Cannabinoid–receptor‐independent cell signalling by ‐acylethanolamines publication-title: Biochemical Journal – volume: 350 start-page: 240 year: 1994 end-page: 244 article-title: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor publication-title: FEBS Letters – volume: 1576 start-page: 255 year: 2002 end-page: 264 article-title: Cloning and molecular characterization of the rat CB2 cannabinoid receptor publication-title: Biochimica Biophysica Acta – volume: 40 start-page: 157 year: 2002 end-page: 167 article-title: Noradrenaline release‐inhibiting receptors on PC12 cells devoid of α ‐ and CB receptors: similarities to presynaptic imidazoline and edg receptors publication-title: Neurochemistry International – volume: 63 start-page: 699 year: 2003 end-page: 705 article-title: Selective ligands and cellular effectors of a G protein‐coupled endothelial cannabinoid receptor publication-title: Molecular Pharmacology – volume: 34 start-page: 605 year: 1988 end-page: 613 article-title: Determination and characterization of a cannabinoid receptor in rat brain publication-title: Molecular Pharmacology – volume: 72 start-page: 1859 year: 2003 end-page: 1870 article-title: Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart publication-title: Life Sciences – volume: 29 start-page: 1 year: 1990 end-page: 43 article-title: ‐acylated glycerophospholipids and their derivatives publication-title: Progress in Lipid Research – volume: 39 start-page: 251 year: 2002 end-page: 257 article-title: CB receptor antagonist SR141716A inhibits Ca ‐induced relaxation in CB receptor‐deficient mice publication-title: Hypertension – volume: 37 start-page: 1889 year: 1994 end-page: 1893 article-title: ( )‐methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability publication-title: Journal of Medicinal Chemistry – volume: 22 start-page: 19 year: 2001 end-page: 22 article-title: Ceramide, a new second messenger of cannabinoid action publication-title: Trends in Pharmacological Sciences – volume: 100 start-page: 4040 year: 2002 end-page: 4048 article-title: Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation publication-title: Blood – volume: 238 start-page: 84 year: 1997 end-page: 86 article-title: Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices publication-title: Neuroscience Letters – volume: 400 start-page: 452 year: 1999 end-page: 457 article-title: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide publication-title: Nature – volume: 21 start-page: 521 year: 1998b end-page: 528 article-title: Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action publication-title: Trends in Neuroscience – volume: 125 start-page: 533 year: 1998a end-page: 541 article-title: The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery publication-title: British Journal of Pharmacology – volume: 42 start-page: 58S issue: Suppl. 11 year: 2002 end-page: 63S article-title: Cardiovascular effects of marijuana publication-title: Journal of Clinical Pharmacology – volume: 33 start-page: 429 year: 1999 end-page: 434 article-title: Mesenteric vasodilation mediated by endothelial anandamide receptors publication-title: Hypertension – volume: 284 start-page: 644 year: 1998 end-page: 650 article-title: SR 144528, the first potent and selective antagonist of the CB cannabinoid receptor publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 346 start-page: 561 year: 1990 end-page: 564 article-title: Structure of a cannabinoid receptor and functional expression of the cloned cDNA publication-title: Nature – volume: 444 start-page: 171 year: 2002 end-page: 181 article-title: Cannabinoids inhibit pre‐ and postjunctionally sympathetic neurotransmission in rat mesenteric arteries publication-title: European Journal of Pharmacology – volume: 30 start-page: 548 year: 2002 end-page: 554 article-title: Dexanabinol (HU‐211) in the treatment of severe closed head injury: a randomized, placebo‐controlled, phase II clinical trial publication-title: Critical Care Medicine – volume: 121 start-page: 1509 year: 1997 end-page: 1511 article-title: Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries publication-title: British Journal of Pharmacology – volume: 122 start-page: 1573 year: 1997 end-page: 1584 article-title: A comparison of EDHF‐mediated and anandamide‐induced relaxations in the rat isolated mesenteric artery publication-title: British Journal of Pharmacology – volume: 134 start-page: 921 year: 2001 end-page: 929 article-title: Mechanisms of anandamide‐induced vasorelaxation in rat isolated coronary arteries publication-title: British Journal of Pharmacology – volume: 53 start-page: 703 year: 1976 end-page: 709 article-title: The effects of Δ9–THC (cannabis) on cardiac performance with or without beta blockade publication-title: Circulation – volume: 57 start-page: 1045 year: 2000 end-page: 1050 article-title: Endocannabinoid 2‐arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide publication-title: Molecular Pharmacology – volume: 278 start-page: 279 year: 1995 end-page: 283 article-title: Novel antagonist implicates the CB cannabinoid receptor in the hypotensive action of anandamide publication-title: European Journal of Pharmacology – volume: 104 start-page: 185 year: 2000 end-page: 191 article-title: A sensitive endocannabinoid assay. The simultaneous analysis of ‐acylethanol‐amines and 2‐monoacylglycerols publication-title: Chemistry and Physics of Lipids – volume: 372 start-page: 686 year: 1994 end-page: 691 article-title: Formation and in‐activation of endogenous cannabinoid anandamide in central neurons publication-title: Nature – volume: 28 start-page: 682 year: 1996 end-page: 686 article-title: Mechanism of the hypotensive action of anandamide in anesthetized rats publication-title: Hypertension – volume: 279 start-page: 129 year: 1991 end-page: 134 article-title: Molecular cloning of a human cannabinoid receptor which is also expressed in testis publication-title: Biochemical Journal – volume: 603 start-page: 102 year: 1993 end-page: 110 article-title: Identification of cannabinoid receptors in cultures of rat cerebellar granule cells publication-title: Brain Research – volume: 71 start-page: 2577 year: 2002 end-page: 2594 article-title: Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function publication-title: Life Sciences – volume: 281 start-page: 151 year: 1976 end-page: 161 article-title: The effects of cannabinoids and other CNS depressants on cell membrane models publication-title: Annals of the New York Academy of Sciences – volume: 141 start-page: 1675 year: 2000 end-page: 1685 article-title: Cannabinoid CB1 receptor‐mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells publication-title: Endocrinology – volume: 384 start-page: 83 year: 1996 end-page: 87 article-title: Molecular characterization of an enzyme that degrades neuromodulatory fatty‐acid amides publication-title: Nature – volume: 243 start-page: 838 year: 1998 end-page: 843 article-title: Detection of an endogenous cannabiminietic molecule, 2‐arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2‐arachidonoylglycerol a possible vasomodulator publication-title: Biochemical and Biophysical Research Communications – volume: 264 start-page: 258 year: 1999 end-page: 267 article-title: Biosynthesis and inactivation of the endocannabinoid 2‐arachidonoylglycerol in circulating and tumoral macrophages publication-title: European Journal of Biochemistry – volume: 57 start-page: 2434 year: 2000 end-page: 2444 article-title: Levels, metabolism, and pharmacological activity of anandamide in CB cannabinoid receptor knockout mice: evidence for non‐CB non‐CB receptor‐mediated actions of anandamide in mouse brain publication-title: Journal of Neurochemistry – volume: 41 start-page: 507 year: 2001 end-page: 534 article-title: Lysophospholipid receptors publication-title: Annual Reviews of Pharmacology and Toxicology – volume: 276 start-page: H2085 year: 1999 end-page: H2093 article-title: Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L‐type Ca channel current publication-title: American Journal of Physiology – volume: 276 start-page: 42639 year: 2001 end-page: 42644 article-title: Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain publication-title: Journal of Biological Chemistry – volume: 316 start-page: 977 year: 1996 end-page: 984 article-title: Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells publication-title: Biochemical Journal – volume: 26 start-page: 532 year: 1984 end-page: 538 article-title: Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes publication-title: Molecular Pharmacology – volume: 117 start-page: 447 year: 1999 end-page: 453 article-title: Myocardial outflow of calcitonin gene‐related peptide in relation to metabolic stress during coronary artery bypass grafting without cardiopulmonary bypass publication-title: Journal of Thoracic and Cardiovascular Surgery – volume: 126 start-page: 457 year: 1999a end-page: 466 article-title: Effect of the cannabinoid receptor agonist WIN55212‐2 on sympathetic cardiovascular regulation publication-title: British Journal of Pharmacology – volume: 375 start-page: 117 year: 1995 end-page: 120 article-title: Occurrence and postmortem generation of anandamide and other long‐chain ‐acylethanolamines in mammalian brain publication-title: FEBS Letters – volume: 12 start-page: 1035 year: 1998 end-page: 1044 article-title: Platelet‐ and macrophage‐derived endogenous cannabinoids are involved in endotoxin‐induced hypotension publication-title: FASEB Journal – volume: 229 start-page: 114 year: 1996 end-page: 120 article-title: An endogenous cannabinoid as an endothelium‐derived vasorelaxant publication-title: Biochemical and Biophysical Research Communications – volume: 375 start-page: 143 year: 1995 end-page: 147 article-title: The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling publication-title: FEBS Letters – volume: 286 start-page: 1146 year: 1998 end-page: 1151 article-title: Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide‐independent coronary vasodilator effect of bradykinin in the rat publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 418 start-page: 117 year: 2001 end-page: 125 article-title: Cannabinoid inhibition of capsaicin‐sensitive sensory neurotransmission in the rat mesenteric arterial bed publication-title: European Journal of Pharmacology – volume: 277 start-page: 1094 year: 1997 end-page: 1097 article-title: Functional role of high–affinity anandamide transport, as revealed by selective inhibition publication-title: Science – volume: 227 start-page: 608 year: 1996 end-page: 614 article-title: Molecular cloning of the novel human G protein‐coupled receptor (GPCR) gene mapped on chromosome 9 publication-title: Biochemical and Biophysical Research Communications – volume: 129 start-page: 645 year: 2000 end-page: 652 article-title: Comparison of novel cannabinoid partial agonists and SR141716A in the guinea‐pig small intestine publication-title: British Journal of Pharmacology – volume: 272 start-page: 22330 year: 1997 end-page: 22339 article-title: A selective inverse agonist for central cannabinoid receptor inhibits mitogen‐activated protein kinase activation stimulated by insulin or insulin‐like growth factor 1. Evidence for a new model of receptor/ligand interactions publication-title: Journal of Biological Chemistry – volume: 35 start-page: 124 year: 1992 end-page: 135 article-title: Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective (aminoalkyl)indole agonists of the cannabinoid receptor publication-title: Journal of Medicinal Chemistry – volume: 126 start-page: 1593 year: 1999 end-page: 1600 article-title: Anandamide‐induced mobilization of cytosolic Ca in endothelial cells publication-title: British Journal of Pharmacology – volume: 15 start-page: 2171 year: 2001b end-page: 2178 article-title: Activation of PAF receptors results in enhanced synthesis of 2‐arachidonoylglycerol (2‐AG) in immune cells publication-title: FASEB Journal – volume: 95 start-page: 191 year: 2002 end-page: 202 article-title: Cardiovascular effects of cannabinoids publication-title: Pharmacology and Therapeutics – volume: 269 start-page: H1859 year: 1995 end-page: H1864 article-title: Anandamide and Δ ‐tetrahydrocannabinol dilation of cerebral arteries is blocked by indomethacin publication-title: American Journal of Physiology – volume: 54 start-page: 180 year: 1998 end-page: 188 article-title: Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation publication-title: Molecular Pharmacology – volume: 48 start-page: 443 year: 1995 end-page: 450 article-title: Comparison of the pharmacology and signal transduction of the human cannabinoid CB and CB receptors publication-title: Molecular Pharmacology – volume: 50 start-page: 83 year: 1995 end-page: 90 article-title: Identification of an endogenous 2‐monoglyceride, present in canine gut, that binds to cannabinoid receptors publication-title: Biochemical Pharmacology – volume: 61 start-page: 352 year: 1993 end-page: 355 article-title: Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase publication-title: Journal of Neurochemistry – volume: 294 start-page: 73 year: 2001 end-page: 82 article-title: Simultaneous measurement of anandamide and 2‐arachidonoylglycerol by polymyxin B‐selective adsorption and subsequent high‐performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock publication-title: Analytical Biochemistry – volume: 71 start-page: 1525 year: 1998 end-page: 1534 article-title: Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes publication-title: Journal of Neurochemistry – volume: 102 start-page: 2873 year: 2000 end-page: 2879 article-title: Insulin prevents cardio‐myocytes from oxidative stress‐induced apoptosis through activation of PI3 kinase/Akt publication-title: Circulation – volume: 86 start-page: 1646 year: 1964 end-page: 1648 article-title: Isolation, structure and partial synthesis of an active constituent of haschish publication-title: Journal of the American Chemical Society – volume: 29 start-page: 307 year: 1986 end-page: 313 article-title: Involvement of G in the inhibition of adenylate cyclase by cannabimimetic drugs publication-title: Molecular Pharmacology – volume: 118 start-page: 2023 year: 1996 end-page: 2028 article-title: Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB receptors on peripheral sympathetic nerves publication-title: British Journal of Pharmacology – volume: 347 start-page: 369 year: 2000 end-page: 373 article-title: The CB cannabinoid receptor is coupled to the activation of protein kinase B/Akt publication-title: Biochemical Journal – volume: 271 start-page: 9902 year: 1996 end-page: 9905 article-title: (–)‐Δ ‐tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor‐mediated inhibition of adenylyl cyclase publication-title: Journal of Biological Chemistry – ident: e_1_2_1_126_1 doi: 10.1161/01.HYP.33.1.429 – ident: e_1_2_1_86_1 doi: 10.1038/sj.bjp.0702337 – ident: e_1_2_1_12_1 doi: 10.1016/S0024-3205(02)02474-8 – ident: e_1_2_1_56_1 doi: 10.1210/en.141.5.1675 – ident: e_1_2_1_66_1 doi: 10.1016/S0008-6363(02)00268-7 – ident: e_1_2_1_88_1 doi: 10.1124/mol.63.3.699 – ident: e_1_2_1_96_1 doi: 10.1016/S0014-2999(01)00940-2 – volume: 294 start-page: 27 year: 2000 ident: e_1_2_1_54_1 article-title: Endocannabinoids and vascular function publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_40_1 doi: 10.1038/73171 – volume: 255 start-page: 1230 year: 1990 ident: e_1_2_1_128_1 article-title: Pravadoline: profile in isolated tissue preparations publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_7_1 doi: 10.1126/science.277.5329.1094 – volume: 346 start-page: 835 year: 2000 ident: e_1_2_1_73_1 article-title: Functional CB1 cannabinoid receptors in human vascular endothelial cells publication-title: Biochemical Journal doi: 10.1042/bj3460835 – ident: e_1_2_1_49_1 doi: 10.1111/j.1476-5381.1973.tb08262.x – ident: e_1_2_1_82_1 doi: 10.1016/S0197-0186(01)00076-6 – ident: e_1_2_1_32_1 doi: 10.1073/pnas.92.8.3376 – ident: e_1_2_1_110_1 doi: 10.1074/jbc.270.8.3726 – ident: e_1_2_1_99_1 doi: 10.1016/S0014-2999(97)01237-5 – ident: e_1_2_1_102_1 doi: 10.1046/j.1471-4159.1998.71041525.x – ident: e_1_2_1_122_1 doi: 10.1007/s001090050287 – ident: e_1_2_1_90_1 doi: 10.1517/13543784.9.7.1553 – ident: e_1_2_1_77_1 doi: 10.1038/346561a0 – ident: e_1_2_1_87_1 doi: 10.1038/sj.bjp.0702452 – ident: e_1_2_1_41_1 doi: 10.1021/ja01062a046 – ident: e_1_2_1_92_1 doi: 10.1016/S0005-2760(98)00110-6 – ident: e_1_2_1_91_1 doi: 10.1111/j.1476-5381.1992.tb09088.x – ident: e_1_2_1_124_1 doi: 10.1038/sj.bjp.0705156 – ident: e_1_2_1_60_1 doi: 10.1074/jbc.M107351200 – ident: e_1_2_1_61_1 doi: 10.1111/j.1476-5381.1996.tb15639.x – ident: e_1_2_1_74_1 doi: 10.1182/blood-2002-05-1444 – ident: e_1_2_1_93_1 doi: 10.1038/sj.bjp.0701361 – ident: e_1_2_1_98_1 doi: 10.1016/S0024-3205(02)02086-6 – ident: e_1_2_1_18_1 doi: 10.1038/384083a0 – ident: e_1_2_1_117_1 doi: 10.1006/bbrc.1998.8187 – ident: e_1_2_1_123_1 doi: 10.1016/S0735-1097(01)01671-0 – ident: e_1_2_1_94_1 doi: 10.1124/jpet.301.3.1020 – ident: e_1_2_1_120_1 doi: 10.1096/fasebj.12.11.1035 – volume: 38 start-page: 151 year: 1986 ident: e_1_2_1_23_1 article-title: Cannabinoid pharmacology publication-title: Pharmacological Reviews – volume: 289 start-page: 1427 year: 1999 ident: e_1_2_1_55_1 article-title: Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1) publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_131_1 doi: 10.1038/sj.bjp.0702127 – ident: e_1_2_1_76_1 doi: 10.1016/0091-3057(91)90349-7 – ident: e_1_2_1_17_1 doi: 10.1038/sj.bjp.0703094 – ident: e_1_2_1_101_1 doi: 10.1016/S0163-7258(02)00258-9 – ident: e_1_2_1_19_1 doi: 10.1021/jm00079a016 – ident: e_1_2_1_20_1 doi: 10.1074/jbc.M008555200 – ident: e_1_2_1_24_1 doi: 10.1046/j.1471-4159.2000.0752434.x – ident: e_1_2_1_95_1 doi: 10.1152/ajpheart.1998.274.1.H375 – ident: e_1_2_1_107_1 doi: 10.1016/0014-5793(95)01194-J – ident: e_1_2_1_5_1 doi: 10.1016/0014-5793(95)01207-U – ident: e_1_2_1_75_1 doi: 10.1074/jbc.M005722200 – ident: e_1_2_1_81_1 doi: 10.1016/S1096-4959(02)00003-9 – volume: 291 start-page: 893 year: 1999 ident: e_1_2_1_84_1 article-title: Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_72_1 doi: 10.1126/science.283.5400.401 – ident: e_1_2_1_29_1 doi: 10.1016/S0166-2236(98)01283-1 – volume: 347 start-page: 369 year: 2000 ident: e_1_2_1_47_1 article-title: The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt publication-title: Biochemical Journal doi: 10.1042/bj3470369 – ident: e_1_2_1_132_1 doi: 10.1038/sj.bjp.0704333 – volume: 29 start-page: 307 year: 1986 ident: e_1_2_1_59_1 article-title: Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs publication-title: Molecular Pharmacology – ident: e_1_2_1_37_1 doi: 10.1146/annurev.pharmtox.41.1.507 – ident: e_1_2_1_30_1 doi: 10.1124/mol.54.1.180 – ident: e_1_2_1_133_1 doi: 10.1006/bbrc.1996.1553 – volume: 57 start-page: 1045 year: 2000 ident: e_1_2_1_48_1 article-title: Endocannabinoid 2‐arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide publication-title: Molecular Pharmacology – ident: e_1_2_1_50_1 doi: 10.1016/S0165-6147(00)01586-8 – volume: 351 start-page: 817 year: 2000 ident: e_1_2_1_10_1 article-title: N‐acyldopamines: novel synthetic CB1 cannabinoid‐receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo publication-title: Biochemical Journal doi: 10.1042/bj3510817 – ident: e_1_2_1_58_1 doi: 10.1124/pr.54.2.161 – ident: e_1_2_1_79_1 doi: 10.1016/S0014-2999(98)00649-9 – volume: 284 start-page: 644 year: 1998 ident: e_1_2_1_104_1 article-title: SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_83_1 doi: 10.1038/sj.bjp.0702483 – volume: 276 start-page: H2085 year: 1999 ident: e_1_2_1_42_1 article-title: Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L‐type Ca2+ channel current publication-title: American Journal of Physiology – ident: e_1_2_1_115_1 doi: 10.1038/42015 – volume: 23 start-page: 295 year: 1971 ident: e_1_2_1_52_1 article-title: General pharmacological actions of some synthetic tetrahydrocannabinol derivatives publication-title: Pharmacological Reviews – ident: e_1_2_1_26_1 doi: 10.1042/bj3310015 – ident: e_1_2_1_21_1 doi: 10.1172/JCI119677 – volume: 238 start-page: 84 year: 1997 ident: e_1_2_1_44_1 article-title: Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices publication-title: Neuroscience Letters doi: 10.1016/S0304-3940(97)00851-3 – ident: e_1_2_1_6_1 doi: 10.1074/jbc.271.17.9902 – ident: e_1_2_1_16_1 doi: 10.1124/pr.54.2.265 – ident: e_1_2_1_108_1 doi: 10.1016/S0009-3084(99)00124-3 – ident: e_1_2_1_116_1 doi: 10.1074/jbc.275.1.605 – ident: e_1_2_1_69_1 doi: 10.1097/00003246-200203000-00009 – ident: e_1_2_1_8_1 doi: 10.1042/0264-6021:3600067 – ident: e_1_2_1_39_1 doi: 10.1111/j.1432-1033.1995.tb20780.x – volume: 26 start-page: 532 year: 1984 ident: e_1_2_1_57_1 article-title: Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes publication-title: Molecular Pharmacology – volume: 278 start-page: 871 year: 1996 ident: e_1_2_1_105_1 article-title: Characterization of two cloned human CB1 isoforms publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 372 start-page: 686 year: 1994 ident: e_1_2_1_28_1 article-title: Formation and in‐activation of endogenous cannabinoid anandamide in central neurons publication-title: Nature doi: 10.1038/372686a0 – ident: e_1_2_1_35_1 doi: 10.1038/sj.bjp.0704565 – ident: e_1_2_1_118_1 doi: 10.1161/01.HYP.28.4.682 – ident: e_1_2_1_130_1 doi: 10.1038/sj.bjp.0702111 – ident: e_1_2_1_14_1 doi: 10.1161/hy0202.102702 – ident: e_1_2_1_85_1 doi: 10.1038/365061a0 – volume: 269 start-page: H1859 year: 1995 ident: e_1_2_1_31_1 article-title: Anandamide and Δ9‐tetrahydrocannabinol dilation of cerebral arteries is blocked by indomethacin publication-title: American Journal of Physiology – ident: e_1_2_1_113_1 doi: 10.1002/j.1552-4604.2002.tb06005.x – ident: e_1_2_1_63_1 doi: 10.1073/pnas.96.24.14136 – ident: e_1_2_1_80_1 doi: 10.1161/01.CIR.103.23.2805 – volume: 48 start-page: 352 year: 1995 ident: e_1_2_1_114_1 article-title: Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase publication-title: Molecular Pharmacology – volume: 281 start-page: 1030 year: 1997 ident: e_1_2_1_71_1 article-title: Cannabinoid‐induced hypotension and bradycardia in rats is mediated by CB1‐like cannabinoid receptors publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_9_1 doi: 10.1096/fj.01-0181com – ident: e_1_2_1_45_1 doi: 10.1111/j.1749-6632.1976.tb27927.x – ident: e_1_2_1_134_1 doi: 10.1038/22761 – ident: e_1_2_1_3_1 doi: 10.1161/01.CIR.102.23.2873 – ident: e_1_2_1_15_1 doi: 10.1016/0006-2952(94)90134-1 – ident: e_1_2_1_100_1 doi: 10.1006/bbrc.1996.1766 – ident: e_1_2_1_64_1 doi: 10.1161/hh2401.101385 – ident: e_1_2_1_127_1 doi: 10.1006/abio.2001.5015 – ident: e_1_2_1_36_1 doi: 10.1111/j.1748-1716.1989.tb08565.x – ident: e_1_2_1_4_1 doi: 10.1016/0014-2999(95)00487-4 – ident: e_1_2_1_13_1 doi: 10.1016/S0167-4781(02)00341-X – ident: e_1_2_1_33_1 doi: 10.1073/pnas.86.23.9584 – ident: e_1_2_1_43_1 doi: 10.1042/bj2790129 – ident: e_1_2_1_11_1 doi: 10.1074/jbc.272.35.22330 – volume: 286 start-page: 1146 year: 1998 ident: e_1_2_1_38_1 article-title: Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide‐independent coronary vasodilator effect of bradykinin in the rat publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_103_1 doi: 10.1016/0014-5793(94)00773-X – ident: e_1_2_1_67_1 doi: 10.1016/S0022-5223(99)70323-5 – ident: e_1_2_1_46_1 doi: 10.1523/JNEUROSCI.17-14-05327.1997 – ident: e_1_2_1_125_1 doi: 10.1038/37371 – ident: e_1_2_1_129_1 doi: 10.1038/sj.bjp.0701546 – ident: e_1_2_1_2_1 doi: 10.1021/jm00038a020 – ident: e_1_2_1_78_1 doi: 10.1016/0006-2952(95)00109-D – ident: e_1_2_1_27_1 doi: 10.1042/bj3160977 – ident: e_1_2_1_109_1 doi: 10.1016/0163-7827(90)90004-5 – volume: 289 start-page: 245 year: 1999 ident: e_1_2_1_62_1 article-title: A role for N‐arachidonylethanolamine (anandamide) as the mediator of sensory nerve‐dependent Ca2+ ‐induced relaxation publication-title: Journal of Pharmacology and Experimental Therapeutics – ident: e_1_2_1_121_1 doi: 10.1111/j.1471-4159.1993.tb03576.x – ident: e_1_2_1_53_1 doi: 10.1073/pnas.87.5.1932 – volume: 42 start-page: 58S issue: 11 year: 2002 ident: e_1_2_1_65_1 article-title: Cardiovascular effects of marijuana publication-title: Journal of Clinical Pharmacology doi: 10.1002/j.1552-4604.2002.tb06004.x – ident: e_1_2_1_51_1 doi: 10.1073/pnas.061029898 – volume: 48 start-page: 443 year: 1995 ident: e_1_2_1_34_1 article-title: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors publication-title: Molecular Pharmacology – ident: e_1_2_1_111_1 doi: 10.1016/S0165-5728(96)00181-6 – ident: e_1_2_1_97_1 doi: 10.1016/S0014-2999(02)01597-2 – volume: 34 start-page: 605 year: 1988 ident: e_1_2_1_22_1 article-title: Determination and characterization of a cannabinoid receptor in rat brain publication-title: Molecular Pharmacology – ident: e_1_2_1_68_1 doi: 10.1161/01.CIR.53.4.703 – ident: e_1_2_1_70_1 doi: 10.1038/sj.bjp.0703902 – ident: e_1_2_1_112_1 doi: 10.1016/j.neuropharm.2005.11.008 – ident: e_1_2_1_119_1 doi: 10.1016/0014-2999(95)00181-J – ident: e_1_2_1_25_1 doi: 10.1046/j.1432-1327.1999.00631.x – ident: e_1_2_1_106_1 doi: 10.1038/sj.bjp.0702351 – ident: e_1_2_1_89_1 doi: 10.1016/0006-8993(93)91304-B |
| SSID | ssj0014663 |
| Score | 1.9762716 |
| SecondaryResourceType | review_article |
| Snippet | Cannabinoids include not only plant-derived compounds (of which Δ9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also synthetic... ABSTRACT Cannabinoids include not only plant‐derived compounds (of which Δ9‐tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also... Cannabinoids include not only plant‐derived compounds (of which Δ 9 ‐tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also... Cannabinoids include not only plant-derived compounds (of which delta9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also... Cannabinoids include not only plant-derived compounds (of which [Delta]9-tetrahydrocannabinol is the primary psychoactive ingredient of cannabis), but also... |
| SourceID | proquest pubmed crossref wiley istex cambridge |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 187 |
| SubjectTerms | Animals Cannabinoid Receptor Modulators - metabolism Cannabinoid Receptor Modulators - pharmacology cannabinoid receptors cannabinoid signalling Cannabinoids Cannabinoids - metabolism Cannabinoids - pharmacology Cardiovascular disease cardiovascular pharmacology Cardiovascular Physiological Phenomena cardiovascular protection Cardiovascular system Cellular biology Fatty Acids, Unsaturated - metabolism Humans Myocardial infarction Pharmacology Proteins Receptors, Cannabinoid - metabolism Signal Transduction |
| Title | Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling |
| URI | https://www.cambridge.org/core/product/identifier/S1464793103006201/type/journal_article https://api.istex.fr/ark:/67375/WNG-JHD6M6NV-1/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1017%2FS1464793103006201 https://www.ncbi.nlm.nih.gov/pubmed/15005177 https://www.proquest.com/docview/231908204 https://www.proquest.com/docview/71710841 |
| Volume | 79 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1Nb9QwEIatqgiJC7R8NZSCD4gDIiX-ShxusKWsKrGHipbeLMdxpFXbZNXsSi2_Ho-dZLttVYQ4Z2w5zkw8Tl4_g9A7ygqpRWZiaYWNAXke59TSmLJUG164DYD1Kt9JOj7iByfiZA2N-rMwgQ8xfHCDyPDvawhwXbSfrpGBXIzDZyGok5Wk1J_hIiwFfv7e4YCQcka-mhoYx2Dd_9kEbPTNHq7zFVbWqQcw5Zd3JaGrOa1flPafoLK_naBFOd1dzItd8_sG6fE_73cDPe6SVvwleNkmWrP1U_QwlLG8eoaaka5r7bbYzbTEsyUL-wpPa-wSTGxWRK840KM_41kzB62S67mjRbg3Lz63cBZ52p63uKshhM-mM9cxKE20J4g_R0f7336OxnFXyCE2XNAsLklpgDhKEy0NAPmTklPLDM1lJXMiLMul5FUpCpLzypjUZFIzTjUkaIRb9gKt101ttxBmorKU5oQRl8mRkmjJCdWVNCKhuVtbI_RxeISqC8dWBSlbpm7NYYSS_ikr00HRoTbH2X1NPgxNZoEIcp_xe-86g6W-OAUpXSbUr8l3dTDeS3-kk2PlDLd731oO2-XeUJE-4RF6O1x14Q__dHRtm0Wr3G6cJG4OIvQyOORyTMLz17IIBbf6-2DV18NjIrNX_9pgGz0KeiYQ-bxG6_OLhd1xqdq8eONj8Q9VWCsR |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB1VrRBcKN-kBeoD4oBIiR07cbhBl7KUdg9VW3qzHMeRVm2TVXdXovx6PHGS7RZUhDhnbDn2jP1sP78BeM3iXGqRmlBaYUOUPA8zZlnI4kQbnrsNgG1YvqNkeMz3TsXpCgy6tzBeH6I_cMPIaOZrDHA8kH5_TRrIBTmeC2GirChh-IhrjTvAgVuwwWEvIuWsmnxqaB2ieXe3icLRN6u4rrCwtFKtYaf_-BMMXUa1zbK0uw62-yHPRjnbns_ybfPzhtbj__7xA7jf4lby0TvaQ1ix1SO44zNZXj2GekdXlXa77HpckMlCDvuKjCviMCYxS7xX4gWkP5BJPUO6kqu5FYxwky-5sPgceTy9mJI2jRA5H09cxUg20Y2I-BM43v18tDMM21wOoeGCpWFBC4OioyzS0qAmf1RwZmPDMlnKjAobZ1LyshA5zXhpTGJSqWPONGI0ym38FFarurLPgcSitIxlNKYOzNGCaskp06U0ImKZW14DeNePoWojcqo8my1Vv_VhAFE3zMq0uuiYnuP8tiJv-yITLwpym_Gbxnd6S315hmy6VKjvoy9qbzhIDpLRiXKGm51zLZrt4DcmpY94AFv9VzcD4LWOrmw9nyq3IaeR64MAnnmPXLRJNBJsaQDer_7eWPXp8ITKdONfC2zB3eHRwb7a_zr6tgn3PL0JOT8vYHV2ObcvHXKb5a-awPwFITwvMA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9QwEB1VrUBcKN-kBeoD4oBIiR07cbjBlmUpsEIVLb1ZjuNIq7ZJ1N2VKL8eT5zNdgsqQpwztvwxYz_Hz28AnrM4l1qkJpRW2BAlz8OMWRayONGG5-4AYFuW7zgZHfL9Y3G8BoPFWxivD9H_cMPIaNdrDPCmKF9fUgZyMY6_hTBPVpQwfMO1wROHKBAZHfQaUs6qTaeG1iGaL642UTf6ahWXBRZWNqoNHPMff0Khq6C23ZWGm1As-uPJKCe781m-a35ekXr8zw7fgdsdaiVvvZvdhTVb3YMbPo_lxX2oB7qqtDtj15OCNEsx7AsyqYhDmMSssF6Jl49-Q5p6hmQlV3MnF-GWXnJm8THyZHo2JV0SIXI6aVzFSDXRrYT4Azgcvv82GIVdJofQcMHSsKCFQclRFmlpUJE_KjizsWGZLGVGhY0zKXlZiJxmvDQmManUMWcaERrlNn4I61Vd2cdAYlFaxjIaUwflaEG15JTpUhoRscxtrgG86qdQdfE4VZ7LlqrfxjCAaDHLynSq6Jic4_S6Ii_7Io2XBLnO-EXrOr2lPj9BLl0q1PfxB7U_2ku-JOMj5Qy3F761bLYD35iSPuIB7PRfXfzjpY6ubD2fKnccp5EbgwAeeYdctkm0AmxpAN6t_t5Y9e7giMp0618L7MDNr3tD9fnj-NM23PLcJiT8PIH12fncPnWwbZY_a8PyF0-tLd8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cannabinoid+pharmacology+in+the+cardiovascular+system%3A+potential+protective+mechanisms+through+lipid+signalling&rft.jtitle=Biological+reviews+of+the+Cambridge+Philosophical+Society&rft.au=Hiley%2C+C+Robin&rft.au=d%2C+William+R&rft.date=2004-02-01&rft.issn=1464-7931&rft.volume=79&rft.issue=1&rft.spage=187&rft_id=info:doi/10.1017%2Fs1464793103006201&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-7931&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-7931&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-7931&client=summon |